Abstract
A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas. A reverse correlation between the binding levels of this mAb and patient survival was demonstrated. To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells. By comparing these cells, the role of MUC1 in tumorigenicity, chemosensitivity and survival under anoikis conditions were assessed. The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma, Clear Cell / drug therapy
-
Adenocarcinoma, Clear Cell / immunology*
-
Adenocarcinoma, Clear Cell / metabolism
-
Aged
-
Animals
-
Anoikis / drug effects
-
Anoikis / physiology
-
Antibodies, Monoclonal*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Female
-
Humans
-
Mice
-
Mice, Nude
-
Middle Aged
-
Mucin-1 / immunology*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / immunology*
-
Ovarian Neoplasms / metabolism
-
Paclitaxel / administration & dosage
-
Paraffin Embedding
-
Prognosis
-
Sialic Acids / metabolism*
-
Survival Rate
Substances
-
Antibodies, Monoclonal
-
Mucin-1
-
Sialic Acids
-
Paclitaxel
-
Cisplatin